Sager Omer, Beyzadeoglu Murat, Dincoglan Ferrat, Gamsiz Hakan, Demiral Selcuk, Uysal Bora, Oysul Kaan, Dirican Bahar, Sirin Sait
Tumori. 2014 Mar-Apr;100(2):184-8. doi: 10.1177/030089161410000211.
Although mostly benign and slow-growing, glomus jugulare tumors have a high propensity for local invasion of adjacent vascular structures, lower cranial nerves and the inner ear, which may result in substantial morbidity and even mortality. Treatment strategies for glomus jugulare tumors include surgery, preoperative embolization followed by surgical resection, conventionally fractionated external beam radiotherapy, radiosurgery in the form of stereotactic radiosurgery or fractionated stereotactic radiation therapy, and combinations of these modalities. In the present study, we evaluate the use of linear accelerator (LINAC)-based stereotactic radiosurgery in the management of glomus jugulare tumors and report our 15-year single center experience.
Between May 1998 and May 2013, 21 patients (15 females, 6 males) with glomus jugulare tumors were treated using LINAC-based stereotactic radiosurgery at the Department of Radiation Oncology, Gulhane Military Medical Academy. The indication for stereotactic radiosurgery was the presence of residual or recurrent tumor after surgery for 5 patients, whereas 16 patients having growing tumors with symptoms received stereotactic radiosurgery as the primary treatment.
Median follow-up was 49 months (range, 3-98). Median age was 55 years (range, 24-77). Of the 21 lesions treated, 13 (61.9%) were left-sided and 8 (38.1%) were right-sided. Median dose was 15 Gy (range, 10-20) prescribed to the 85%-100% isodose line encompassing the target volume. Local control defined as either tumor shrinkage or the absence of tumor growth on periodical follow-up neuroimaging was 100%.
LINAC-based stereotactic radiosurgery offers a safe and efficacious management strategy for glomus jugulare tumors by providing excellent tumor growth control with few complications.
虽然颈静脉球瘤大多为良性且生长缓慢,但极易局部侵犯相邻血管结构、低位脑神经及内耳,这可能导致严重的发病率甚至死亡率。颈静脉球瘤的治疗策略包括手术、术前栓塞后手术切除、常规分割外照射放疗、立体定向放射外科或分割立体定向放射治疗形式的放射外科,以及这些方式的联合应用。在本研究中,我们评估基于直线加速器(LINAC)的立体定向放射外科在颈静脉球瘤治疗中的应用,并报告我们单中心15年的经验。
1998年5月至2013年5月期间,21例颈静脉球瘤患者(15例女性,6例男性)在盖勒罕内军事医学院放射肿瘤学系接受了基于LINAC的立体定向放射外科治疗。立体定向放射外科的适应证为5例患者术后存在残留或复发性肿瘤,而16例有症状的肿瘤生长患者接受立体定向放射外科作为主要治疗。
中位随访时间为49个月(范围3 - 98个月)。中位年龄为55岁(范围24 - 77岁)。在治疗的21个病灶中,13个(61.9%)位于左侧,8个(38.1%)位于右侧。中位剂量为15 Gy(范围10 - 20 Gy),处方给包含靶体积的85% - 100%等剂量线。定义为肿瘤缩小或在定期随访神经影像上无肿瘤生长的局部控制率为100%。
基于LINAC的立体定向放射外科通过提供良好的肿瘤生长控制且并发症少,为颈静脉球瘤提供了一种安全有效的治疗策略。